Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound

David A. Sanchez, David Schairer, Chaim Tuckman-Vernon, Jason Chouake, Allison Kutner, Joy Makdisi, Joel M. Friedman, Joshua D. Nosanchuk, Adam J. Friedman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Candida spp. infection in the context of burn wounds leads to invasive disease with a 14-70% mortality rate. Unfortunately, current administrations of AmB, an important therapeutic demonstrating minimal resistance, are only available via potentially cytotoxic IV infusions. In order to circumvent these sequelae, we investigated the efficacy of nanoparticle encapsulated AmB (AmB-np) as a topical therapeutic against Candida spp. (drug release equilibrated solubilized AmB [AmB-sol] included as control). Clinical strains demonstrated equal or enhanced killing efficacy with 72.4-91.1% growth reduction by 4 hours. AmB-nps resulted in statistically significant reduction of fungal biofilm metabolic activity ranging from 80% to 95% viability reduction (P<. 0.001). Using a murine full-thickness burn model, AmB-np exhibited a quicker efficiency in fungal clearance versus AmB-sol by day three, although wound healing rates were similar. These data support the concept that AmB-np can function as a topical antifungal in the setting of a burn wound. From the Clinical Editor: The control of fungal infections with Candida species remains a challenge in the context of burn wounds. A nanoencapsulated topical amphotericin-B compound was studied in a murine model of full thickness burn injury, showing remarkable efficacy in controlling Candida infection. This may become a viable alternative to the potentially toxic intravenous formulations.

Original languageEnglish (US)
Pages (from-to)269-277
Number of pages9
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume10
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Candida
Amphotericin B
Nanoparticles
Wounds and Injuries
Polymethyl Methacrylate
Sols
Mycoses
Poisons
Biofilms
Infection
Wound Healing
Thermodynamic properties
Mortality
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • Amphotericin B
  • Burn wounds
  • Candida spp.
  • Nanoparticles
  • Topical antifungal

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound. / Sanchez, David A.; Schairer, David; Tuckman-Vernon, Chaim; Chouake, Jason; Kutner, Allison; Makdisi, Joy; Friedman, Joel M.; Nosanchuk, Joshua D.; Friedman, Adam J.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 10, No. 1, 01.2014, p. 269-277.

Research output: Contribution to journalArticle

Sanchez, David A. ; Schairer, David ; Tuckman-Vernon, Chaim ; Chouake, Jason ; Kutner, Allison ; Makdisi, Joy ; Friedman, Joel M. ; Nosanchuk, Joshua D. ; Friedman, Adam J. / Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2014 ; Vol. 10, No. 1. pp. 269-277.
@article{062470d43c434d9f9b092333b58d99ec,
title = "Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound",
abstract = "Candida spp. infection in the context of burn wounds leads to invasive disease with a 14-70{\%} mortality rate. Unfortunately, current administrations of AmB, an important therapeutic demonstrating minimal resistance, are only available via potentially cytotoxic IV infusions. In order to circumvent these sequelae, we investigated the efficacy of nanoparticle encapsulated AmB (AmB-np) as a topical therapeutic against Candida spp. (drug release equilibrated solubilized AmB [AmB-sol] included as control). Clinical strains demonstrated equal or enhanced killing efficacy with 72.4-91.1{\%} growth reduction by 4 hours. AmB-nps resulted in statistically significant reduction of fungal biofilm metabolic activity ranging from 80{\%} to 95{\%} viability reduction (P<. 0.001). Using a murine full-thickness burn model, AmB-np exhibited a quicker efficiency in fungal clearance versus AmB-sol by day three, although wound healing rates were similar. These data support the concept that AmB-np can function as a topical antifungal in the setting of a burn wound. From the Clinical Editor: The control of fungal infections with Candida species remains a challenge in the context of burn wounds. A nanoencapsulated topical amphotericin-B compound was studied in a murine model of full thickness burn injury, showing remarkable efficacy in controlling Candida infection. This may become a viable alternative to the potentially toxic intravenous formulations.",
keywords = "Amphotericin B, Burn wounds, Candida spp., Nanoparticles, Topical antifungal",
author = "Sanchez, {David A.} and David Schairer and Chaim Tuckman-Vernon and Jason Chouake and Allison Kutner and Joy Makdisi and Friedman, {Joel M.} and Nosanchuk, {Joshua D.} and Friedman, {Adam J.}",
year = "2014",
month = "1",
doi = "10.1016/j.nano.2013.06.002",
language = "English (US)",
volume = "10",
pages = "269--277",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound

AU - Sanchez, David A.

AU - Schairer, David

AU - Tuckman-Vernon, Chaim

AU - Chouake, Jason

AU - Kutner, Allison

AU - Makdisi, Joy

AU - Friedman, Joel M.

AU - Nosanchuk, Joshua D.

AU - Friedman, Adam J.

PY - 2014/1

Y1 - 2014/1

N2 - Candida spp. infection in the context of burn wounds leads to invasive disease with a 14-70% mortality rate. Unfortunately, current administrations of AmB, an important therapeutic demonstrating minimal resistance, are only available via potentially cytotoxic IV infusions. In order to circumvent these sequelae, we investigated the efficacy of nanoparticle encapsulated AmB (AmB-np) as a topical therapeutic against Candida spp. (drug release equilibrated solubilized AmB [AmB-sol] included as control). Clinical strains demonstrated equal or enhanced killing efficacy with 72.4-91.1% growth reduction by 4 hours. AmB-nps resulted in statistically significant reduction of fungal biofilm metabolic activity ranging from 80% to 95% viability reduction (P<. 0.001). Using a murine full-thickness burn model, AmB-np exhibited a quicker efficiency in fungal clearance versus AmB-sol by day three, although wound healing rates were similar. These data support the concept that AmB-np can function as a topical antifungal in the setting of a burn wound. From the Clinical Editor: The control of fungal infections with Candida species remains a challenge in the context of burn wounds. A nanoencapsulated topical amphotericin-B compound was studied in a murine model of full thickness burn injury, showing remarkable efficacy in controlling Candida infection. This may become a viable alternative to the potentially toxic intravenous formulations.

AB - Candida spp. infection in the context of burn wounds leads to invasive disease with a 14-70% mortality rate. Unfortunately, current administrations of AmB, an important therapeutic demonstrating minimal resistance, are only available via potentially cytotoxic IV infusions. In order to circumvent these sequelae, we investigated the efficacy of nanoparticle encapsulated AmB (AmB-np) as a topical therapeutic against Candida spp. (drug release equilibrated solubilized AmB [AmB-sol] included as control). Clinical strains demonstrated equal or enhanced killing efficacy with 72.4-91.1% growth reduction by 4 hours. AmB-nps resulted in statistically significant reduction of fungal biofilm metabolic activity ranging from 80% to 95% viability reduction (P<. 0.001). Using a murine full-thickness burn model, AmB-np exhibited a quicker efficiency in fungal clearance versus AmB-sol by day three, although wound healing rates were similar. These data support the concept that AmB-np can function as a topical antifungal in the setting of a burn wound. From the Clinical Editor: The control of fungal infections with Candida species remains a challenge in the context of burn wounds. A nanoencapsulated topical amphotericin-B compound was studied in a murine model of full thickness burn injury, showing remarkable efficacy in controlling Candida infection. This may become a viable alternative to the potentially toxic intravenous formulations.

KW - Amphotericin B

KW - Burn wounds

KW - Candida spp.

KW - Nanoparticles

KW - Topical antifungal

UR - http://www.scopus.com/inward/record.url?scp=84890983286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890983286&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2013.06.002

DO - 10.1016/j.nano.2013.06.002

M3 - Article

C2 - 23770066

AN - SCOPUS:84890983286

VL - 10

SP - 269

EP - 277

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 1

ER -